B. Metzler seel. Sohn & Co. AG Boosts Stock Position in Certara, Inc. $CERT

B. Metzler seel. Sohn & Co. AG boosted its position in Certara, Inc. (NASDAQ:CERT) by 59.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 200,397 shares of the company’s stock after purchasing an additional 74,956 shares during the quarter. B. Metzler seel. Sohn & Co. AG owned approximately 0.13% of Certara worth $2,449,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. First Horizon Corp purchased a new position in shares of Certara in the 3rd quarter worth approximately $30,000. Versant Capital Management Inc raised its stake in shares of Certara by 66.7% during the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after acquiring an additional 1,153 shares in the last quarter. Osaic Holdings Inc. lifted its position in Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares during the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in Certara during the second quarter valued at approximately $59,000. Finally, Global Retirement Partners LLC boosted its stake in Certara by 45.0% in the third quarter. Global Retirement Partners LLC now owns 5,636 shares of the company’s stock valued at $69,000 after acquiring an additional 1,749 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Stephens cut their price target on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, December 12th. Rothschild & Co Redburn set a $10.00 price objective on Certara in a report on Friday, November 21st. Weiss Ratings reissued a “sell (d+)” rating on shares of Certara in a research report on Monday, December 29th. BMO Capital Markets initiated coverage on Certara in a research note on Thursday, November 13th. They set a “market perform” rating and a $9.00 target price on the stock. Finally, KeyCorp reduced their target price on Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Certara has a consensus rating of “Hold” and a consensus target price of $11.10.

Certara Stock Down 0.3%

CERT stock opened at $7.04 on Tuesday. The stock has a market capitalization of $1.12 billion, a PE ratio of -704.00 and a beta of 1.50. Certara, Inc. has a 52 week low of $6.04 and a 52 week high of $15.38. The company has a quick ratio of 2.05, a current ratio of 2.05 and a debt-to-equity ratio of 0.27. The firm has a 50 day moving average of $8.14 and a 200 day moving average of $9.72.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The company had revenue of $103.65 million for the quarter, compared to analyst estimates of $103.23 million. Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.15 EPS. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. Sell-side analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current year.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.